by admin | Aug 8, 2025 | press-releases-rss
This post was originally published on this site.– Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting – –...
by admin | Jul 29, 2025 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...
by admin | Jun 5, 2025 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...
by admin | May 15, 2025 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...
by admin | May 13, 2025 | press-releases-rss
This post was originally published on this site.– Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M – – Promising early signal...
by admin | May 1, 2025 | press-releases-rss
This post was originally published on this site.– Award recipients Honored at the American Urological Association’s 2025 Annual Meeting – – Fellowship designed to support the development of outstanding clinical cancer research investigators to...